| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.8 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |